Exploratory Study of Autoantibody Profiling in Drug‐Induced Liver Injury with an Autoimmune Phenotype

Craig Lammert, Chengsong Zhu, Yun Lian, Indu Raman, George Eckert, Quan‐Zhen Li, Naga Chalasani – 1 September 2020 – Drug‐induced liver injury (DILI) sometimes presents with an autoimmune hepatitis‐like phenotype (AI‐DILI), and it is challenging to distinguish it from de novo autoimmune hepatitis (AIH). We conducted a study to identify autoantibodies unique to AI‐DILI by profiling serum autoantibodies.

Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis

Julie Steen Pedersen, Marte Opseth Rygg, Viggo Bjerregaard Kristiansen, Beth Hærstedt Olsen, Reza Rafiolsadat Serizawa, Jens Juul Holst, Sten Madsbad, Lise Lotte Gluud, Flemming Bendtsen, Nicolai Jacob Wewer Albrechtsen – 1 September 2020 – Nonalcoholic fatty liver disease (NAFLD) is associated with impaired hepatic actions of glucagon and insulin. Glucagon and amino acids are linked in an endocrine feedback circuit, the liver–alpha cell axis, that may be disrupted by NAFLD.

Time to Conversion to an Everolimus‐Based Regimen: Renal Outcomes in Liver Transplant Recipients From the EVEROLIVER Registry

Faouzi Saliba, Sébastien Dharancy, Ephrem Salamé, Filoména Conti, Daniel Eyraud, Sylvie Radenne, Térésa Antonini, Olivier Guillaud, Jean Guguenheim, Martine Neau‐Cransac, Eléonora Demartin, Guillaume Lasailly, Christophe Duvoux, Rodolphe Sobesky, Audrey Coilly, Sylvie Tresson, Valérie Cailliez, Olivier Boillot, Georges Philippe Pageaux, Didier Samuel, Yvon Calmus, Jérôme Dumortier – 31 August 2020 – Longterm use of a calcineurin inhibitor (CNI)–based regimen is one of the major reasons for chronic renal failure in liver transplantation recipients (LTRs).

Subscribe to